Roland B. Walter, MD, PhD, MS
I studied medicine in Switzerland. While there are many differences between the U.S. and Swiss medical systems, there’s one thing that’s the same: the personality of patients with acute leukemia. I continue to be impressed with their strength, courage and spirit. They face difficult treatments and onerous side effects with grace and gratitude. Aside from the patients themselves, I enjoy the complex, interdisciplinary nature of treating people with this disease. There are all these different aspects of medicine that come together, and I think that’s unique.
A successful patient-physician partnership is based on transparency. With that in mind, I see it as my role to clearly explain the nuances of your disease and share what the science has to say about treatment, including both conventional and experimental options. With that as our basis, we will develop a treatment plan that best matches your life values and goals. For many of the treatment decisions, there is no absolute right or wrong; I want you to feel empowered to make decisions that fit your beliefs and wishes.
Specialty: Medical Oncology
Adult Blood and Marrow Transplantation
I am a board-certified hematologist who specializes in treating patients with acute myeloid leukemia (AML). My research focuses on developing novel antibody-based therapies for AML. Antibodies are proteins in the blood that attack invaders like viruses. I’m studying how to direct antibodies to identify and kill AML cells. Some of the antibodies in development work by engaging a patient’s own immune cells. My colleagues and I create new therapeutics for AML in partnership with other investigators at Fred Hutchinson Cancer Research Center and industry partners. These collaborations have led to the development of five new drugs that have subsequently been brought forward to the clinic for testing in people with AML.
Dr. Walter received the Leukemia & Lymphoma Society’s Scholar in Clinical Research Award, which supports original investigation into the treatment of hematologic malignancies.
The “A” Award provides funding for scientists who want to establish a career in pediatric oncology research.
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
Your care team
SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.